JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weerts, E. M.
Right arrow Articles by Griffiths, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weerts, E. M.
Right arrow Articles by Griffiths, R. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ZOLPIDEM TARTRATE

Vol. 285, Issue 1, 41-53, April 1998

Zolpidem Physical Dependence Assessed Across Increasing Doses Under a Once-Daily Dosing Regimen in Baboons1

Elise M. Weerts, Nancy A. Ator, Doreen M. Grech2 and Roland R. Griffiths

Behavioral Biology Research Center, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

The current study examined behavioral effects and possible development of physical dependence after once-daily doses of zolpidem (0, 1.0, 3.2, 10.0, 32.0 mg/kg intragastrically [i.g.]) in three baboons. Each dose was administered for 17 days and then the dose was increased; the 32.0 mg/kg dose was administered for 27 days. Baboons had access to food pellets for 20 hr/day beginning 15 min after dosing. Each day, baboons were presented with a fine motor task. Observation sessions were conducted 1 hr after dosing on days 1, 10, 12 and 14 of each dose condition and after termination of drug dosing. On days 10 and 14 of each dose condition, vehicle and flumazenil (5 mg/kg i.m.) were administered, respectively. Zolpidem increased the number of pellets obtained by two of three baboons. Vomit and/or retch and grimace (signs believed to be indicative of abdominal discomfort) were observed in one or two baboons during all zolpidem dose conditions (1.0-32.0 mg/kg). Time to complete the fine motor task increased dose-dependently in all three baboons, and incoordination was observed during the task in two baboons at 10.0 and 32.0 mg/kg. Analysis of blood plasma showed that measurable levels of zolpidem were present 24 hr after dosing in all drug conditions. The signs of flumazenil-precipitated withdrawal were summarized on a 9-point scale. Scores ranged from 1 to 5 in the 1.0 mg/kg condition, from 2 to 5 in the 3.2 and 10.0 mg/kg conditions and from 4 to 6 in the 32.0 mg/kg condition. Signs that were considered intermediate in severity were observed. Specifically, tremor, jerk and/or rigidly braced posture was observed in one baboon at 1.0 mg/kg, two baboons at the next two doses and all three baboons at 32.0 mg/kg. Vomit and/or retch also occurred in two baboons at dose conditions above 1.0 mg/kg. Discontinuation of zolpidem dosing after 78 to 79 days resulted in mild withdrawal signs (e.g., number of pellets obtained were lower and number of 1-min intervals increased in which eyes were closed, or in which lying down, head lower than torso posture and/or withdrawn posture were observed) on the first day in two baboons. The peak withdrawal scores were 4 or 5 on days 5 to 10; two baboons vomited and/or retched and all three baboons showed tremor, jerk and/or rigidly braced posture. Thus, zolpidem produced physical dependence under once-daily dosing conditions, and the severity of the withdrawal syndrome can be characterized as intermediate.


0022-3565/98/2851-0041$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J PsychopharmacolHome page
T. Capua and C. M. Shapiro
Commentary on a critique for the Journal of Psychopharmacology: NICE -excellence or eccentricity? Reflections on the z-drugs as hypnotics review
J Psychopharmacol, January 1, 2007; 21(1): 114 - 117.
[PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. R. Mirza and E. O. Nielsen
Do Subtype-Selective {gamma}-Aminobutyric AcidA Receptor Modulators Have a Reduced Propensity to Induce Physical Dependence in Mice?
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1378 - 1385.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
L. R Rappa, M. Larose-Pierre, D. R Payne, N. E Eraikhuemen, D. M Lanes, and M. L Kearson
Detoxification from High-Dose Zolpidem Using Diazepam
Ann. Pharmacother., April 1, 2004; 38(4): 590 - 594.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
I. A. Liappas, P. N. Malitas, N. P. Dimopoulos, O. E. Gitsa, A. I. Liappas, Ch. K. Nikolaou, and G. N. Christodoulou
Zolpidem dependence case series: possible neurobiological mechanisms and clinical management
J Psychopharmacol, January 1, 2003; 17(1): 131 - 135.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Lelas, L. R. Gerak, and C. P. France
Antagonism of the Discriminative Stimulus Effects of Positive gamma -Aminobutyric AcidA Modulators in Rhesus Monkeys Discriminating Midazolam
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 902 - 908.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.